Associated Genetic Biomarkers
ITGAV status serves as an inclusion eligibility criteria in 1 clinical trial, of which 0 are open and 1 is closed. Of the trial that contains ITGAV status as an inclusion criterion, 1 is phase 2 (0 open).
Trials with ITGAV status in the inclusion eligibility criteria most commonly target colorectal carcinoma .
The most frequent alterations to serve as inclusion eligibility criteria are ITGAV Expression and ITGAV Overexpression .
Abituzumab, folfiri regimen, cetuximab, and placebo are the most frequent therapies in trials with ITGAV as an inclusion criteria .
Significance of ITGAV in Diseases
Colorectal Carcinoma +
ITGAV is an inclusion criterion in 1 clinical trial for colorectal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains ITGAV status and colorectal carcinoma as inclusion criteria, 1 is phase 2 (0 open) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.